PDD 00017273
目录号 : GC32784
PDD 00017273是一种高选择性的，聚（ADP-核糖）糖水解酶（PARG）抑制剂，IC50值和Kd值分别为 26nM和1.45nM。
Cas No.:1945950-21-9
Sample solution is provided at 25 µL, 10mM.
PDD 00017273 is a highly selective inhibitor of poly(ADP-ribose) glycohydrolase (PARG), with IC₅₀ and Kd values of 26nM and 1.45nM, respectively[1]. PDD 00017273 induces apoptosis by modulating PARG-related signaling pathways[2]. In addition, PDD 00017273 can increase the sensitivity of cancer cells to radiotherapy and chemotherapy[3-4].
In vitro, treatment of preosteoblastic MC3T3-E1 cells with PDD 00017273 (1μM) significantly increases intracellular poly(ADP-ribose) (PAR) levels while promoting alkaline phosphatase (ALP) activity and mineralization. Moreover, PDD 00017273 upregulates the mRNA expression levels of osteocalcin (Ocn) and bone sialoprotein (Bsp), as well as the transcriptional inducers osterix (Osx) and activating transcription factor 4 (Atf4), thereby accelerating the osteoblast differentiation process in MC3T3-E1 cells[5]. Long-term treatment of human colorectal cancer cells HCT116 with PDD 00017273 (10μM and 30μM) induces resistance, forming the HCT116-resistant PDD 00017273 cell line (HCT116RPDD). In HCT116RPDD cells, the PARG gene undergoes a Glu352Gln mutation, and the PARP1 gene undergoes a Lys134Asn mutation, with a significant reduction in PARP1 protein levels[6].
References:
[1] James DI, Smith KM, Jordan AM, et al. First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib. ACS Chem Biol. 2016 Nov 18;11(11):3179-3190.
[2] Mori Y, Akizuki Y, Honda R, et al. Intrinsic signaling pathways modulate targeted protein degradation. Nat Commun. 2024 Jul 2;15(1):5379.
[3] Fabbrizi MR, Nickson CM, Hughes JR, et al. Targeting OGG1 and PARG radiosensitises head and neck cancer cells to high-LET protons through complex DNA damage persistence. Cell Death Dis. 2024 Feb 17;15(2):150.
[4] Ali R, Alblihy A, Miligy IM, et al. Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers. Oncogene. 2021 Apr;40(14):2496-2508.
[5] Sasaki Y, Nakatsuka R, Inouchi T, et al. Inhibition of Poly (ADP-Ribose) Glycohydrolase Accelerates Osteoblast Differentiation in Preosteoblastic MC3T3-E1 Cells. Int J Mol Sci. 2022 May 2;23(9):5041.
[6] Tsuda K, Kurasaka C, Ogino Y, et al. Genomic and biological aspects of resistance to selective poly(ADP-ribose) glycohydrolase inhibitor PDD00017273 in human colorectal cancer cells. Cancer Rep (Hoboken). 2023 Feb;6(2):e1709.
PDD 00017273是一种高选择性的，聚（ADP-核糖）糖水解酶（PARG）抑制剂，IC50值和Kd值分别为 26nM和1.45nM[1]。PDD 00017273通过调节PARG相关的信号通路来诱导细胞凋亡[2]。此外，PDD 00017273还可增加癌细胞对放疗和化疗的敏感性[3-4]。
在体外，PDD 00017273（1μM）处理小鼠前成骨细胞MC3T3-E1细胞，可显著增加细胞内聚腺苷二磷酸核糖（PAR）水平，同时促进细胞碱性磷酸酶（ALP）活性和矿化能力。此外，PDD 00017273还可上调成骨细胞分化标志物骨钙素（Ocn）和骨桥蛋白（Bsp）的mRNA表达水平，以及转录诱导因子osterix（Osx）和激活转录因子4（Atf4）的mRNA表达水平，从而加速MC3T3-E1细胞的成骨细胞分化过程[5]。PDD00017273（10μM和30μM）长期处理人结直肠癌细胞HCT116，诱导其产生耐药性，形成HCT116耐药PDD00017273细胞系（HCT116RPDD）。HCT116RPDD细胞中PARG基因发生Glu352Gln突变，PARP1基因发生Lys134Asn突变，同时PARP1蛋白水平显著降低[6]。
| Cell experiment [1]: | |
Cell lines | MC3T3-E1 cells (mouse preosteoblastic cell line) |
Preparation Method | MC3T3-E1 cells were maintained in Minimum Essential Medium (no ascorbic acid) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C, 5% CO₂. Cells were seeded on 6-, 48-, or 96-well plates at a density of 6.6×10³ cells/cm² and cultured for 2 days in maintenance medium. The medium was then changed to differentiation medium containing 1% ascorbic acid, 0.2% hydrocortisone, 2% β-glycerophosphate, 10% FBS, and 1% penicillin-streptomycin in the presence of PDD 00017273 (1μM) or dimethylsulfoxide (DMSO, solvent). The differentiation medium was replaced every 4 days, and the cells were allowed to differentiate for 0, 7, 14, 21, and 28 days for various experiments |
Reaction Conditions | 1μM; 28 days |
Applications | PDD 00017273 significantly increased intracellular PAR levels, promoted ALP activity, and enhanced mineralization. PDD 00017273 also upregulated the mRNA expression levels of osteocalcin (Ocn), bone sialoprotein (Bsp), and osterix (Osx). PDD 00017273 accelerated osteoblast differentiation in MC3T3-E1 cells. |
References: | |
| Cas No. | 1945950-21-9 | SDF | |
| Canonical SMILES | O=S(C1=CC2=C(N(CC3=CC(C)=NN3C)C(N(CC4=CN=C(C)S4)C2=O)=O)C=C1)(NC5(C)CC5)=O | ||
| 分子式 | C23H26N6O4S2 | 分子量 | 514.62 |
| 溶解度 | DMSO : 50 mg/mL (97.16 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9432 mL | 9.7159 mL | 19.4318 mL |
| 5 mM | 0.3886 mL | 1.9432 mL | 3.8864 mL |
| 10 mM | 0.1943 mL | 0.9716 mL | 1.9432 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet